Through analysis of genome-wide expression profiling, Sotiriou et al. found out that topoisomerase II-alpha (TOP2A) expression could effectively predict the response of anthracycline (epirubicin) for estrogen receptor– (ER–) negative breast cancer patients who received neoadjuvant chemotherapy (NCT) [5]. This evidence concerns the gene ESR1 and breast carcinoma.